1887

Abstract

Examination of 682 strains representing four species of mycobacteria (, and ) and seven species of nocardiae (, and ) indicated that, with the exception of and , resistance to rifampin (20 μg/ml) is a useful property for describing these species. Resistance to lysozyme (300 to 500 U/ml) is taxonomically useful for delineating all 11 species.

Loading

Article metrics loading...

/content/journal/ijsem/10.1099/00207713-27-3-176
1977-07-01
2022-10-04
Loading full text...

Full text loading...

/deliver/fulltext/ijsem/27/3/ijs-27-3-176.html?itemId=/content/journal/ijsem/10.1099/00207713-27-3-176&mimeType=html&fmt=ahah

References

  1. Arioli V., Pallanza R., Furesz S., Carniti G. 1967; Rifampicin: a new rifamycin. I. Bacteriological studies. Arzneim. Forsch. 17:523–528
    [Google Scholar]
  2. Clark J., Wallace A. 1967; The susceptibility of mycobacteria to rifamide and rifampicin. Tubercle 48:144–150
    [Google Scholar]
  3. Denis-Bottin C. 1972; Activité ((in vitro)) de la rifampicine sur des souches de mycobactéries tuberculeuses et atypiques. Acta Tuberc. Pneumol. Belg. 63:127–139
    [Google Scholar]
  4. Goodfellow M., Orchard V. A. 1974; Antibiotic sensitivity of some nocardioform bacteria and its value as a criterion for taxonomy. J. Gen. Microbiol. 83:375–387
    [Google Scholar]
  5. Gordon R. E., Barnett D. A., Handerhan J. E., Pang C. H.-N. 1974; Nocardia coeliaca, Nocardia autotrophica, and the nocardin strain. Int. J. Syst. Bacteriol. 24:54–63
    [Google Scholar]
  6. Hennebert A. 1969; Activité antimycobactérienne de la rifampicine «in vitro)) dans différents milieux. Acta Tuberc. Pneumol. Belg. 60:348–354
    [Google Scholar]
  7. Hobby G. L., Lenert T. F. 1968; The antimycobacterial activity of rifampin. Am. Rev. Respir. Dis. 97:713–714
    [Google Scholar]
  8. Hobby G. L., Lenert T. F., Maier-Engallena J. 1969; Experimental observations on the antimycobacterial activity of rifampin. Proc. Soc. Exp. Biol. Med. 131:323–326
    [Google Scholar]
  9. Jenne J. W., Beggs W. H. 1973; Correlation of in vitro and in vivo kinetics with clinical use of isoniazid, ethambutol, and rifampin. Am. Rev. Respir. Dis. 107:1013–1021
    [Google Scholar]
  10. Karlson A. G. 1970; Comparison of three mediums for rifampin-susceptibility tests of mycobacteria. Am. Rev. Respir. Dis. 101:765–767
    [Google Scholar]
  11. Le Lirzin M., Boisvert H. 1971; Teneur des souches de mycobactéries atypiques, pathogènes pour l’homme, en variants résistant a la rifampicine et en variants résistant a l’éthambutol, sur milieu de Loewenstein-Jensen. Ann. Inst. Pasteur Paris 120:549–559
    [Google Scholar]
  12. Lorian V., Finland M. 1969; In vitro effect of rifampin on mycobacteria. Appl. Microbiol 17:202207
    [Google Scholar]
  13. Lucchesi M., Mancini P. 1970; Antimycobacterial activity of rifampicin. Antibiot. Chemother 16:431443
    [Google Scholar]
  14. McClatchy J. K., Waggoner R. F., Lester W. 1969; In vitro susceptibility of mycobacteria to rifampin. Am. Rev. Respir. Dis. 100:234–236
    [Google Scholar]
  15. Manten A., van Wijngaarden L. J., van Klingeren B. 1969; Rifampicin-susceptibility and rifampicin-resistance in mycobacteria. Acta Tuberc. Pneumol. Belg. 60:329–334
    [Google Scholar]
  16. Molavi A., Weinstein L. 1971; In vitro susceptibility of atypical mycobacteria to rifampin. Appi. Microbiol. 22:23–25
    [Google Scholar]
  17. Nitti V. 1970; Experimental and clinical studies on the antituberculous activity of rifampicin alone or combined with other drugs. Antibiot. Chemother 16:444470
    [Google Scholar]
  18. Nitti V., Catena E., Ninni A., Di Filippo A. 1966; Indagini sperimentali sull’attività antimicobatterica della rifampicina. Arch. Tisiol. Pneumol. (Montevideo) 21:867–910
    [Google Scholar]
  19. Pallanza R., Arioli V., Furesz S., Bolzoni G. 1967; Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations. Arzneim. Forsch 17:529534
    [Google Scholar]
  20. Rynearson T. K., Shrontis J. S., Woiinsky E. 1971; Rifampin: in vitro effect on atypical mycobacteria. Am. Rev. Respir. Dis. 104:272–274
    [Google Scholar]
  21. Schröder K. H., Hensel J., Scheuch V. 1969; Die Sensibilitätsprüfung von M. tuberculosis und atypischen Mykobakterien gegen Ethambutol, Capreomycin und Rifampicin. Prax. Pneumol. 23:683–694
    [Google Scholar]
  22. Tacquet A., Devulder B., Martin J. C., Daniel H., Le Bouffant L. 1969; Activité antimycobactérienne de la rifampicine: etudes ((in vitro)) et «in vivo)). Acta Tuberc. Pneumol. Belg. 60:366–389
    [Google Scholar]
  23. Tanzil H. O. K., Chatim A., Rachim A., Judanarso D. 1972; ((In vitro)) action of rifampicin on typical and atypical mycobacteria. Acta Tuberc. Pneumol. Belg. 63:140–147
    [Google Scholar]
  24. Verbiet L., Gyselen A. 1968; Antituberculosis activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am. Rev. Respir. Dis. 98:923–932
    [Google Scholar]
  25. Zierski M., Wozniak S., Tomaszkiewicz L. 1969; The antimycobacterial activity of rifampicin ((in vitro)). Acta Tuberc. Pneumol. Belg. 60:341–347
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/ijsem/10.1099/00207713-27-3-176
Loading
/content/journal/ijsem/10.1099/00207713-27-3-176
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error